Core Viewpoint - Ocugen, Inc. has successfully closed an underwritten registered direct offering of 15 million shares at $1.50 per share, resulting in net proceeds of $20.85 million, aimed at supporting its operations and extending its cash runway into Q4 2026 [1][2]. Group 1: Offering Details - The offering consisted of 15,000,000 shares priced at $1.50 each, leading to net proceeds of $20.85 million after expenses [1]. - The financing was led by RTW Investments, with participation from both new and existing investors [1]. - Oppenheimer & Co. served as the sole book-running manager for the offering [2]. Group 2: Use of Proceeds - The net proceeds will be allocated for general corporate purposes, capital expenditures, working capital, and administrative expenses [2]. - The funding is expected to extend the company's cash runway into the fourth quarter of 2026 [2]. Group 3: Company Overview - Ocugen, Inc. is a biotechnology leader focused on gene therapies for blindness diseases, utilizing a modifier gene therapy platform to address complex diseases caused by multiple gene network imbalances [5]. - The company is developing programs for inherited retinal diseases and blindness conditions affecting millions globally, including retinitis pigmentosa, Stargardt disease, and geographic atrophy [5].

Core Viewpoint - Ocugen, Inc. has announced the pricing of an underwritten offering of 15 million shares of common stock at $1.50 per share, aiming for gross proceeds of $22.5 million, expected to close around January 22, 2026 [1]. Group 1: Offering Details - The offering consists of 15,000,000 shares priced at $1.50 each, resulting in gross proceeds of $22.5 million before expenses [1]. - The offering is led by RTW Investments, with participation from both new and existing investors [1]. - Oppenheimer & Co. is the sole book-running manager for the offering [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for general corporate purposes, capital expenditures, working capital, and general and administrative expenses [2]. Group 3: Company Overview - Ocugen, Inc. is a biotechnology leader focused on gene therapies for blindness diseases, with a modifier gene therapy platform aimed at addressing significant unmet medical needs [5]. - The company is developing programs for inherited retinal diseases and blindness diseases, including retinitis pigmentosa, Stargardt disease, and geographic atrophy [5].

Core Thesis - REGENXBIO Inc. presents a bullish investment opportunity due to its strong pipeline, strategic partnerships, and favorable market positioning in gene therapies [1][5]. Company Overview - REGENXBIO is a clinical-stage biotechnology company focused on gene therapies utilizing its proprietary NAV Technology platform, specifically AAV8 and AAV9 vectors [2]. - The lead program, suragene lomparvovec (sura-vec, ABBV-RGX-314), targets wet age-related macular degeneration and diabetic retinopathy, significantly reducing the need for repeated injections [2]. Clinical Programs - The company has the largest retinal gene therapy program to date, with over 1,200 patients enrolled in pivotal trials ATMOSPHERE and ASCENT [3]. - REGENXBIO is also advancing RGX-202 for Duchenne muscular dystrophy and RGX-121 for MPS II, with RGX-121 showing an 82% median reduction in a cerebrospinal fluid biomarker linked to neurodevelopmental stabilization [3]. Financial Position - As of early 2026, REGENXBIO has a solid liquidity position of approximately $302 million, supported by recent non-dilutive financings [4]. - This capital is expected to fund operations into early 2027, excluding significant milestone payments from AbbVie related to late-stage trials [4]. Market Position and Strategy - The company is strategically positioned in competitive markets favoring durable, long-acting therapies, with Phase 2 data in wet AMD showing favorable comparisons to emerging peers [4]. - AbbVie's commercial infrastructure provides a significant execution advantage for REGENXBIO [4]. Upcoming Catalysts - An FDA PDUFA date for RGX-121 is set for February 2026, with pivotal readouts for wet AMD expected in late 2026, indicating a catalyst-rich investment profile [5]. - The current valuation of REGENXBIO is seen as underappreciating the depth of its pipeline and the strength of its partnerships [5].

Summary of Regenxbio FY Conference Call (January 14, 2026) Company Overview - **Company**: Regenxbio (NasdaqGS: RGNX) - **Key Speakers**: Curran Simpson (CEO), Mitch Chan (CFO), Dr. Steve Pakola (CMO) [1] Industry and Technology - **Industry**: Gene Therapy - **Technology**: AAV (Adeno-Associated Virus) gene therapy with over 5,000 patients dosed [2][3] - **Focus**: Development of new capsids to enhance therapeutic efficacy and safety [5] Core Points and Arguments Pipeline and Product Development - **BLA Review**: The company has a Biologics License Application (BLA) under review for the Hunter program, with a PDUFA date of February 8, 2026 [8][22]. - **Late-Stage Programs**: Top-line readouts expected for two late-stage programs: Duchenne program (RGX-202) in Q2 2026 and wet AMD program (RGX-314) with AbbVie later in 2026 [4][8]. - **Duchenne Program**: Aiming to provide functional benefits to children with Duchenne muscular dystrophy, with pivotal data showing significant improvements in patient outcomes [10][11][19]. - **Wet AMD Program**: RGX-314 is positioned as a potential first non-rare gene therapy approved, with significant commercial readiness efforts in collaboration with AbbVie [9][25]. Manufacturing and Scalability - **Manufacturing Capabilities**: The company has advanced manufacturing processes, capable of producing 2,500 doses per year for RGX-202 and up to 350,000 doses for RGX-314 [28][29]. - **Quality Control**: Achieved an 80% full capsid level in batches, which is critical for safety and efficacy [29]. Safety and Efficacy - **Immune Suppression Regimen**: A proactive immune suppression strategy has been implemented to enhance safety and efficacy, allowing for higher dosing without significant adverse effects [36][37]. - **Clinical Outcomes**: Positive safety profiles and functional benefits observed in patients, with significant improvements in NSAA scores [19][17]. Additional Important Content - **Global Expansion**: Plans for expanding clinical studies outside the U.S. to address broader patient needs [21][39]. - **Partnerships**: Collaboration with AbbVie for the wet AMD program, leveraging their existing sales force and expertise in ophthalmology [43][44]. - **Market Potential**: The company is targeting significant unmet needs in rare diseases and chronic retinal diseases, with a focus on long-term patient outcomes and reducing treatment burdens [31][27]. Conclusion - **Future Outlook**: Regenxbio is positioned for a transformative year with multiple late-stage catalysts, a strong manufacturing base, and a commitment to patient-centric outcomes in gene therapy [31].

NGN-401 Clinical Development and Trial Design - NGN-401 is being developed as a potential one-time, best-in-class gene therapy for Rett syndrome, showing durable multidomain improvements across the disease spectrum[8] - The Embolden registrational trial, aligned with the FDA, is a single trial for ages ≥ 3 years, with multiple participants dosed in 4Q'25[8] - The Embolden trial is a single-arm, baseline-controlled, open-label trial of NGN-401 in females with Rett Syndrome, using a one-time 1E15 vg dose in patients ≥ 3 years[30, 31] - The primary endpoint for the Embolden trial at 12 months is a responder-based composite endpoint, requiring a 35% response rate (7 of 20 participants) for success[32] Market Opportunity and Commercial Readiness - Rett syndrome presents a multi-billion-dollar market opportunity for disease-modifying gene therapy, with an estimated prevalence of ~15,000 – 20,000 patients in major markets (US, EU, and UK)[9, 13] - Payors are receptive to reimbursement for Rett syndrome treatments, valuing functional changes that are clinically meaningful and show improvements in activities of daily living[13] - Early commercial-readiness activities are underway, including positioning Embolden clinical trial sites for rapid conversion to commercial sites at launch[9, 42] Phase 1/2 Clinical Trial Data - Interim Phase 1/2 data showed 100% of participants demonstrated functional improvements across core disease domains (fine motor/hand function, gross motor/ambulation, and communication)[24] - A total of 35 developmental milestones were gained in the Phase 1/2 trial, with no plateau observed out to 24 months[24] - In the Phase 1/2 trial, 88% of participants achieved an improved CGI-I score[24] Upcoming Milestones and Financial Position - Complete dosing of the Embolden trial is expected in 2Q'26, with presentation of 12+ months Phase 1/2 data for all 10 participants planned for mid-2026[10] - The company has a strong cash balance expected to fund operations through Embolden data readout, BLA submission, and key pre-launch activities (as of 1Q'28)[49]

Group 1: Market Overview - At the start of 2026, the stock market shows signs of instability, with concerns about the potential bubble in the artificial intelligence sector, yet the S&P 500 has reached unprecedented highs [2] - Despite market fears, there are opportunities for investors to identify undervalued stocks that could yield significant returns in the mid to long-term [2] Group 2: Rocket Pharmaceuticals (RCKT) - Rocket Pharmaceuticals is a clinical-stage gene therapy developer focused on rare diseases, with shares dropping from approximately $6.59 to about $2.50 due to a trial-related issue, currently priced at $3.80 [3] - The stock has seen a mild positive trend with an 8% year-to-date rally, and the company is advancing its gene therapy programs, notably in Phase 2 trials for Danon disease [5] - The average Wall Street 12-month price target for RCKT is $8.63, indicating a potential upside of 127% by the end of 2026 [6] Group 3: Fiserv (FISV) - Fiserv is a well-established company in the global payments and financial infrastructure sector, with a significant drop of 40% in stock price due to a poor earnings report, currently priced at $66.79 [8] - Analysts suggest FISV is undervalued based on fundamentals, with expectations of at least a 40% rally in 2026 as the digital payments sector grows [10] - Congressional trading patterns show Representative Gilbert Cisneros purchased FISV shares, highlighting potential investor confidence [11] Group 4: Intel (INTC) - Intel's stock price is currently at $47.29, significantly lower than competitors Nvidia and AMD, despite gaining ground through 2025 [12] - The company is strategically important for the U.S. and is on a path to potentially become the second-largest microchip foundry, surpassing Samsung [14] - Intel's significance is underscored by the geopolitical risks associated with semiconductor production concentrated in Taiwan [15]

Core Insights - Ocugen, Inc. is hosting a conference call and live webcast to discuss data from the OCU410 Phase 2 ArMaDa clinical trial, focusing on patients who have completed one year since treatment [1] - The conference call is scheduled for January 15, 2026, at 8:30 a.m. ET, featuring key opinion leaders and Ocugen's executive leadership [1][2] Company Overview - Ocugen, Inc. is a biotechnology leader specializing in gene therapies for blindness diseases, utilizing a modifier gene therapy platform that addresses complex diseases caused by imbalances in multiple gene networks [3] - The company is developing therapies for inherited retinal diseases and blindness diseases, including retinitis pigmentosa, Stargardt disease, and geographic atrophy, which affect millions globally [3]

Group 1 - UniQure (NASDAQ:QURE) is considered a promising stock to buy under $50, with recent price target adjustments from analysts [1][2] - Stifel lowered its price target for UniQure to $40 from $50 while maintaining a Buy rating, following a comprehensive review of the biotech sector [1] - Mizuho reduced its price target for UniQure to $33 from $60, maintaining an Outperform rating, due to regulatory concerns regarding the Phase I/II studies for AMT-130 [2][3] Group 2 - The FDA indicated that current data for AMT-130 likely lacks the primary evidence required for a Biologics License Application (BLA), leading to a reduced probability of success and a delayed market launch by one year [2][3] - Despite these challenges, there is optimism about AMT-130's long-term potential, with a follow-up Type A meeting with the FDA scheduled for Q1 2026 to establish a new path forward [3]

EVERY BREAKTHROUGH BEGINS WITH BELIEF January 2026 Corporate Presentation Disclaimer Forward Looking Statements This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current expectations and beliefs of the management of Neurogene, as well as assumptions made by, and ...

Core Insights - Ocugen, Inc. announced positive Phase 1 GARDian1 trial results for OCU410ST, a novel modifier gene therapy for Stargardt disease, published in the peer-reviewed journal Nature Eye [1][2] Group 1: Clinical Trial Results - The Phase 1 GARDian1 trial demonstrated robust efficacy and safety outcomes, indicating a favorable safety and tolerability profile for OCU410ST [3][4] - Among six patients with gradable Fundus Auto Fluorescence images, atrophic lesion growth was reduced by 54% in treated eyes compared to untreated eyes over 12 months [5] - Treated eyes showed a 50% slower lesion expansion rate compared to untreated eyes, below published natural history rates [5] - Visual acuity improved in treated eyes, with a gain of +6 letters in Best Corrected Visual Acuity (BCVA) compared to a decline in untreated eyes [5] - No drug-related serious adverse events were reported during the trial [5] Group 2: Disease Background - Stargardt disease is the most common form of inherited macular degeneration, affecting over 100,000 individuals in the U.S. and Europe, characterized by progressive central vision loss [3][7] - Currently, there are no FDA-approved treatments for Stargardt disease, highlighting a critical unmet medical need [3][7] Group 3: Future Developments - The ongoing Phase 2/3 GARDian3 trial is progressing ahead of schedule, with anticipated enrollment completion in the first quarter of 2026 [4] - The company plans to file a Biologics License Application (BLA) in the first half of 2027, aiming for three regulatory submissions within three years [4] Group 4: Technology Overview - OCU410ST utilizes an AAV5 delivery platform to deliver the RORA gene to the retina, addressing multiple pathophysiological pathways linked to Stargardt disease [6] - The therapy aims to provide a gene-agnostic modification strategy that could benefit patients regardless of their underlying ABCA4 mutation [4][6] Group 5: Company Overview - Ocugen, Inc. focuses on discovering and developing novel gene therapies for blindness diseases, aiming to address significant unmet medical needs through innovative approaches [8]